Search results for "MEK1"
showing 3 items of 3 documents
MEK1 Required for Invasive Growth of mIMCD3 renal Cells in a 3D Collagen Matrix
2004
Branching morphogenesis is an essential process during kidney development: This process controls epithelialization of the metanephric mesenchyme during the induction of branching structures and in this way determines the number of nephrons. Various grow factors, such HGF, have been implicated in branching morphogenesis in renal cells, including mIMCD3 ( murine inner medullary collecting duct) and MDCK cells. Growth factors which induce branching morphogenesis in renal cells also activate the MEK1/ERK pathway. The authors analyzed the potential role that this pathway might play in branching morphogenesis. The authors show that PD98059, a specific inhibitor of MEK1,inhibits branching of mIMCD…
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition …
2007
The molecular mechanisms behind the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) are not completely understood and cannot be explained by the inhibition of the cyclooxygenase (COX) enzymes COX-1 and COX-2 alone. We previously reported that both the selective COX-1 inhibitor SC-560 and the selective COX-2 inhibitor CAY10404 exhibit anti-tumor effects in human hepatoma cells. NSAID inhibitors have many COX-independent actions and, among others, the mitogen-activated protein kinase (MAPK) pathways are targets for NSAIDs. Here, we examined the role of MEK/ERK1/2 signaling in the anti-neoplastic effects of both selective COX-1 and COX-2 inhibitors in two human hepato…
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of r…
2015
BackgroundAcquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In this study, we evaluated the spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with specific mechanisms of resistance.MethodsWe compiled clinical and genetic data from 100 patients with 132 tissue samples obtained at progression on BRAFi therapy from 3 large, previously published studies of BRAFi resistance. These samples were subjected to whole-exome sequencing and/or polymerase chain reaction-based genetic testing.ResultsAmong 132 samples, putative resistance mechanisms were identified in 58%, including NRAS o…